Although in the last reported quarter, growth in industrial and applied segments was in low-single digits, the company performed well on strong demand for its chemical analysis, chromatography and mass spectrometry products. It also maintained growth momentum in clinical diagnostics and immunodiagnostic businesses, and witnessed strong demand in its health-care market channel. Raised Guidance Buoys Optimism: Thermo Fisher recently raised its 2019 adjusted earnings per share guidance to $12.16-$12.26 from $12.08-$12.22 mentioned earlier. The Zacks Consensus Estimate for earnings of $12.25 remains within the company's projected range. This indicates that it will likely be able to maintain its ongoing bullish momentum throughout the rest of the year. Which Way Are Estimates Heading? The estimate revision trend for the current year is impressive. Over the past 90 days, the Zacks Consensus Estimate for the company's earnings has inched up 0.4% to $12.25.